In the post-genomic era, there is an increasing and urgent need for managing and visualizing big data. Data complexity and size will turn information growth into knowledge growth only if presented in a comprehensive and user-friendly way. In such a context, the information technology community collaborates in a multidisciplinary manner with other scientific fields searching for and/or developing tools and services for data management and visualization. We have previously developed DruGeVar, a comprehensive database that triangulates drugs with genes and pharmacogenomic biomarkers to serve clinical pharmacogenomics. To empower its functionality, we explored and implemented new visualization tools, such as POWER-BI (Microsoft), which allows for interactive visualization. Herein, we describe the synergy of POWER-BI and DruGeVar, focusing on cancer genomics data in light of translational pharmacogenomics.

Keywords:
Databases, DruGeVar, Pharmacogenomics, POWER-BI, Visualization interface
1.
Chen CP, Zhang C-Y: Data-intensive applications, challenges, techniques and technologies: a survey on Big Data. Inf Sci 2014;275:314-347.
2.
Keim D, Andrienko G, Fekete J-D, Görg C, Kohlhammer J, Melançon G: Visual analytics: definition, process, and challenges; in Kerren A, Stasko J, Fekete J-D, North C (eds): Information Visualization - Human-Centered Issues and Perspectives. Berlin, Springer, 2008, pp 154-175.
3.
Chen H, Chiang RH, Storey VC: Business intelligence and analytics: from big data to big impact. MIS Quarterly 2012;36:1165-1188.
4.
Sarma AC, Girão J: Identities in the future internet of things. Wireless Pers Commun 2009;49:353-363.
5.
Miorandi D, Sicari S, De Pellegrini F, Chlamtac I: Internet of things: vision, applications and research challenges. Ad Hoc Netw 2012;10:1497-1516.
6.
Manovich L: What is visualisation? Vis Stud 2011;26:36-49.
7.
Chen C: Information visualization. Wiley Interdiscip Rev Comput Stat 2010;2:387-403.
8.
Friendly M, Denis DJ: Milestones in the History of Thematic Cartography, Statistical Graphics, and Data Visualization. http://www.datavis.ca/milestones, 2001.
9.
Friendly M: Visions and re-visions of Charles Joseph Minard. J Educ Behav Stat 2002;27:31-51.
10.
Cairo A: The Functional Art: An Introduction to Information Graphics and Visualization. Berkeley, New Riders, 2012.
11.
Dalabira E, Viennas E, Daki E, Komianou A, Bartsakoulia M, Poulas K, Katsila T, Tzimas G, Patrinos GP: DruGeVar: an online resource triangulating drugs with genes and genomic biomarkers for clinical pharmacogenomics. Public Health Genomics 2014;17:265-271.
12.
Viennas E, Komianou A, Mizzi C, Stojiljkovic M, Mitropoulou C, Muilu J, Vihinen M, Grypioti P, Papadaki S, Pavlidis C: Expanded national database collection and data coverage in the FINDbase worldwide database for clinically relevant genomic variation allele frequencies. Nucleic Acids Res 2017;45:D846-D853.
13.
Makedon F, Karkaletsis V, Maglogiannis I: Overview: Computational analysis and decision support systems in oncology. Oncol Rep 2006;15:971-974.
14.
Karacapilidis N, Koukouras D: A web-based system for supporting collaboration towards resolving oncology issues. Oncol Rep 2006;15:1101-1107.
15.
Tsiliki G, Karacapilidis N, Christodoulou S, Tzagarakis M: Collaborative mining and interpretation of large-scale data for biomedical research insights. PLoS One 2014;9:e108600.
16.
Katsila T, Konstantinou E, Lavda I, Malakis H, Papantoni I, Skondra L, Patrinos GP: Pharmacometabolomics-aided pharmacogenomics in autoimmune disease. EBioMedicine 2016;5:40-45.
17.
Balasopoulou A, Patrinos GP, Katsila T: Pharmacometabolomics informs viromics toward precision medicine. Front Pharmacol 2016;7:411.
18.
Katsila T, Patrinos GP: Whole genome sequencing in pharmacogenomics. Front Pharmacol 2015;6:61.
19.
Manolio TA, Fowler DM, Starita LM, Haendel MA, MacArthur DG, Biesecker LG, Worthey E, Chisholm RL, Green ED, Jacob HJ: Bedside back to bench: building bridges between basic and clinical genomic research. Cell 2017;169:6-12.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.